Disease · MONDO_0005309

spinal fracture

6 sourcesdiseases-2026-09-18-0.1.0

Cite this record

ConductScience Library. spinal fracture. Diseases, record MONDO_0005309. Release diseases-2026-09-18-0.1.0, 18 Sept 2026. https://conductscience.org/library/diseases/MONDO_0005309

On this page

Disease

Names and IDs as Open Targets gives them. Its IDs in MeSH, Orphanet, the Disease Ontology and the NCI Thesaurus are those Open Targets states for it.

Name: spinal fracture; Open Targets
Open Targets ID: MONDO_0005309; Open Targets
Other names: Fracture, Spinal, Fractures, Spinal, Spinal Fractures, bone fracture of vertebral column, fracture, vertebral, vertebral column bone fracture, vertebral fracture; Open Targets
MeSH: D016103; MeSH
Highest stage of its drugs: Phase 3, for 5 of its 5 drugs, from ClinicalTrials.gov; Open Targets

Drugs5

The drugs Open Targets' clinical reports study for the disease, the highest stage first, then the most trial reports. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Drug	ChEMBL ID	Type	Open Targets' stage	Stage reported by	Reports	Of them trials	Trials shown here	Source
ZOLEDRONIC ACID	CHEMBL4303669	Small molecule	Phase 3	ClinicalTrials.gov	2	2	2	Drugs and targets
PARATHYROID HORMONE	CHEMBL2108078	Protein	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RALOXIFENE HYDROCHLORIDE	CHEMBL1116	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
RISEDRONIC ACID	CHEMBL923	Small molecule	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets
ROMOSOZUMAB	CHEMBL2107874	Antibody	Phase 3	ClinicalTrials.gov	1	1	1	Drugs and targets

Targets4

The targets ChEMBL's mechanism records give for the disease's drugs, through Open Targets, the most drugs first. A mechanism record says what a drug acts on, not that the target causes the disease.

Target	Protein	Its drugs that act on it	Mechanisms	Highest stage of those drugs	Gene in Genes	Source
FDPS	Farnesyl pyrophosphate synthase	2	Farnesyl diphosphate synthase inhibitor	Phase 3	https://conductscience.org/library/genes/2224	Drugs and targets
ESR2	Estrogen receptor beta	1	Estrogen receptor beta modulator	Phase 3	https://conductscience.org/library/genes/2100	Drugs and targets
PTH1R	Parathyroid hormone/parathyroid hormone-related peptide receptor	1	Parathyroid hormone receptor agonist	Phase 3	https://conductscience.org/library/genes/5745	Drugs and targets
SOST	Sclerostin	1	Sclerostin inhibitor	Phase 3	https://conductscience.org/library/genes/50964	Drugs and targets

Trials6

Trials an Open Targets clinical report links to the disease, posted results first, then the largest. A trial is shown when the release's checks confirm its link to the disease and Drugs and targets shows its link to one of the disease's drugs.

Trial	Title	Phase	Participants	Results first posted	Conditions	Drugs	Linked by	Source
NCT01575834	Efficacy and Safety of Romosozumab Treatment in Postmenopausal Women With Osteoporosis	Phase 3	7,180	2018-11-08	Postmenopausal Osteoporosis	ROMOSOZUMAB	Its record names the disease	ClinicalTrials.gov
NCT00439647	Efficacy in Reducing Fractures and Safety of Zoledronic Acid in Men With Osteoporosis	Phase 3	1,199	2011-11-16	Male Osteoporosis	ZOLEDRONIC ACID	Its record names the disease	ClinicalTrials.gov
NCT00799266	An Efficacy and Safety Trial of Intravenous Zoledronic Acid Twice Yearly in Osteoporotic Children Treated With Glucocorticoids	Phase 3	34	2019-07-05	Osteoporosis	ZOLEDRONIC ACID	Open Targets' reading of its record	ClinicalTrials.gov
NCT00670319	Comparison of Raloxifene Hydrochloride and Placebo in the Treatment of Postmenopausal Women With Osteoporosis	Phase 3	7,705		Osteoporosis, Postmenopausal	RALOXIFENE HYDROCHLORIDE	Open Targets' reading of its record	ClinicalTrials.gov
NCT00172081	TOP: Recombinant Human Parathyroid Hormone (ALX1-11) on Fracture Incidence in Women With Postmenopausal Osteoporosis	Phase 3	2,532		Osteoporosis	PARATHYROID HORMONE	Its record names the disease	ClinicalTrials.gov
NCT00268632	IMPACT Study (Improving Measurements of Persistence on "ACtonel" Treatment)	Phase 3			Osteoporosis	RISEDRONIC ACID	Open Targets' reading of its record	ClinicalTrials.gov

Comparisons in its trials7

Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Zoledronic Acid vs Placebo: Number of Participants With First Clinical Vertebral Fracture	1 of 588	3 of 611	1,199	NCT00439647	Trial comparisons
Zoledronic Acid vs Placebo: Number of Participants With First Clinical Fracture	6 of 588	11 of 611	1,199	NCT00439647	Trial comparisons
Zoledronic Acid vs Placebo: Number of Participants With First Non-vertebral Fracture	5 of 588	8 of 611	1,199	NCT00439647	Trial comparisons
Zoledronic Acid vs Placebo: serious adverse events	149 of 588	154 of 611	1,199	NCT00439647	Trial comparisons
Zoledronic Acid vs Placebo: deaths from any cause	0 of 18	0 of 16	34	NCT00799266	Trial comparisons
Zoledronic Acid vs Placebo: serious adverse events	5 of 18	1 of 16	34	NCT00799266	Trial comparisons
Zoledronic Acid vs Placebo: Number of Participants With New Vertebral Fractures at Month 12	0 of 17	2 of 16	33	NCT00799266	Trial comparisons

Papers from its trials6

The papers the trials shown here list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
17244788	RESULT	1	PubMed
38573517	DERIVED	1	PubMed
34228102	DERIVED	1	PubMed
23113482	DERIVED	1	PubMed
20927038	DERIVED	1	PubMed
17339618	DERIVED	1	PubMed

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
Drug links and their checks, from Drugs and targets: 2026-09-18; Drugs and targets
ClinicalTrials.gov, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
PubMed, for the checks: 2026-11-06; PubMed
MeSH, for the checks: 2026-11-10; MeSH

Sources 6

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this disease from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/diseases/v1/MONDO_0005309

GET https://conductscience.org/api/diseases/v1/MONDO_0005309/drugs

API reference For AI assistants